Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 20/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aripiprazole SCHEMBL8255 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475637 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475638 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL982189 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29438823 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL7097505 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL236666 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL5147095 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL30958766 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL31174198 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102389-A1 | METHOD FOR SIMULTANEOUSLY REGULATING CRYSTAL FORMS AND CRYSTAL HABITS OF ARIPIPRAZOLE DRUG AND ARIPIPRAZOLE CRYSTAL FORMS THEREOF | UNIV GUANGDONG TECHNOLOGY (CN) | 2026-04-16 | — | — | US | claimed |
| WO-2025125888-A1 | ARIPIPRAZOLE AND TRAMADOL COMPOSITIONS WITH POTENTIATION EFFECTS AND HIGH ANALGESIC EFFICACY USEFUL FOR THE TREATMENT OF NEUROPATHIC PAIN | CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL I.P.N. (MX) | 2025-06-19 | — | — | WO | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2023107966-A1 | SALT AND SOLID FORMS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND ANALOGS | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| CN-115379842-A | Method for administering aripiprazole injection preparation | 大塚制药株式会社 | 2022-11-22 | — | — | CN | claimed |
| EP-3941470-A1 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-01-26 | — | — | EP | claimed |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4297723-B1 | MICRONEEDLE COMPOSITIONS AND METHODS OF DELIVERY USING THE SAME | BRIGHAM & WOMENS HOSPITAL INC (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026102455-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR MICRONEEDLE-BASED TRANSDERMAL DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122029617-A | Protein markers for neurodegenerative diseases | 香港科技大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3789029-A4 | RADIATION SENSITIVITY ENHANCING COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT | Korea Institute of Radiological & Medical Sciences (KR) | 2022-03-09 | — | — | EP | disclosed |
| US-20220054482-A1 | METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION | OTSUKA PHARMA CO LTD (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3941470-A1 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941470-A1 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, HTR2C, TPH1 | DRD2 21/4885HTR1A 9/4885HTR2A 14/4885 |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TPH2, TPH1, HTR1D | DRD2 23/4885HTR1A 6/4885HTR2A 5/4885 |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | DRD2 106/4885HTR1A 38/4885HTR2A 37/4885 |
| US-20260102389-A1 | METHOD FOR SIMULTANEOUSLY REGULATING CRYSTAL FORMS AND CRYSTAL HABITS OF ARIPIPRAZOLE DRUG AND ARIPIPRAZOLE CRYSTAL FORMS THEREOF | ALB, AP2S1, ATG4A | DRD2 1292/4885HTR1A 369/4885HTR2A 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.